Carcell and OBiO enter into a strategic agreement for lipid nanoparticle services
Carcell Biopharma (“Carcell”) and OBiO Technology (“OBiO”) are pleased to announce their collaboration to provide lipid nanoparticle...
top of page
Carcell News Center
Democratizing Drug Delivery: Lipid Nanoparticles Changing the Game
Imagine having access to cutting-edge cationic lipids that can revolutionize drug delivery – at affordable prices. At Carcell, we...
Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board
SINGAPORE and SHANGHAI, Dec. 19, 2022 -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey...
Carcell Welcomes Prof. Jianzhu Chen and Dr. Hagop Youssoufian as New Advisors
A warm welcome to two new advisors to Carcell Biopharma! Prof. Jianzhu Chen of MIT joins Carcell's Scientific Advisory Board, and Dr....
Carcell Biopharma closes an oversubscribed financing round led by Hyfinity Investments
Advancing the next generation of cell and gene therapies via a "platform of platforms" model SINGAPORE, Nov. 1, 2021 -- Carcell Biopharma...
bottom of page